ClinicalTrials.gg
CompletedNCT03359785Updated Feb 28, 2024Results posted

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

A Phase 2 interventional study of Luvadaxistat and Matching Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
14th of 16
31 · median 165
Started
2018
with 1 other
Phase 2
6 of 16
1 open now
Registered
4th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 14th largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 2, and was the 4th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.

Read the detailed description

The drug being tested in this study is called luvadaxistat. Luvadaxistat is being tested to treat people with schizophrenia.

Participants will be randomly assigned to one of the two treatment sequences which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Luvadaxistat 500 milligrams (mg) followed by matching placebo
  • Matching placebo followed by luvadaxistat 50 mg

Participants will receive luvadaxistat 500 mg during the treatment period in which they are assigned to luvadaxistat. Following an interim analysis, there will be a study-wide decision about whether to treat the additional participants with luvadaxistat 500 mg during the active treatment period to or treat them with luvadaxistat 50 mg during this period. After the interim analysis, the participant and study doctor will not be aware of which luvadaxistat dose is being used.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) greater than or equal to (>=) 18.5 and less than or equal to (\<=) 40.0 (kilogram per square meter [kg/m\^2]) at the Screening Visit.
  • With a current , Fifth Edition (DSM-5) diagnosis of schizophrenia who are receiving stable antipsychotic therapy (no increase, no decrease greater than [>] 20% in dose in the preceding 2 months).
  • Positive and Negative Syndrome Scale (PANSS) negative symptom factor score (NSFS) >= 15, stable screening and baseline PANSS NSFS (\< 25% change).
  • PANSS total score \<= 90; stable screening and baseline PANSS total score (less than [\<] 20% change).
  • Receiving stable (no increase, no decrease > 25% in dose in the preceding 2 months)antipsychotic medication at doses not to exceed risperidone 6 mg or its equivalent. Concomitant treatment with a subtherapeutic dose of a second antipsychotic may be permitted with sponsor or designee approval if used as a hypnotic (maximum of quetiapine 300 mg or its equivalent once daily at bedtime) and participants does not show morning sedation as per the investigator opinion, but not if it is used for positive psychosis symptoms. Under this exception, the total daily dose the second antipsychotic will not have to be included in the calculation of the 6 mg/day risperidone-equivalent limit.

Exclusion criteria

Exclusion Criteria:

  • Has a history of cancer () excluding treated basal cell carcinoma or treated stage 0 (in situ) cervical carcinoma.
  • Has a history of significant multiple and/or severe allergies (example [eg], food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
  • Has a with Fridericia's correction method (QTcF) > 450 milliseconds [ms] (males) or > 470 ms (females) confirmed with one repeat testing, at the Screening Visit or Check-in.
  • Has a positive alcohol or drug screen for disallowed substances, including amphetamines, barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4-methylenedioxymethamphetamine, phencyclidine, or nonprescribed benzodiazepines or opiates.
  • Is positive for surface antigen (HBsAg), antibodies, or has by history (confirmatory testing is allowed; most sensitive test should take precedence).
  • Had major surgery, donated or lost 250 milliliter [mL] of blood within 4 weeks prior to the prestudy (screening) visit.
  • Has a known to any component of the formulation of luvadaxistat.
  • Has a history of significant skin reactions (hypersensitivity) to adhesives, metals or plastic.
  • Is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or participants who within the past year prior to Screening have attempted suicide. Participants who have positive answers on item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) (based on the past year) prior to randomization are excluded.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Luvadaxistat 500 mg, then Placebo

    Participants first received luvadaxistat 500 mg orally once daily (QD) for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.

    Drug: Luvadaxistat · Drug: Matching Placebo

  • Experimental
    Placebo, then Luvadaxistat 500 mg

    Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 500 mg orally QD for 8 days during treatment period 2.

    Drug: Luvadaxistat · Drug: Matching Placebo

  • Experimental
    Luvadaxistat 50 mg, then Placebo

    Participants first received luvadaxistat 50 mg orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received matching placebo orally QD for 8 days during treatment period 2.

    Drug: Luvadaxistat · Drug: Matching Placebo

  • Experimental
    Placebo, then Luvadaxistat 50 mg

    Participants first received matching placebo orally QD for 8 days during treatment period 1. After a washout of 14 to 21 days, participants then received luvadaxistat 50 mg orally QD for 8 days during treatment period 2.

    Drug: Luvadaxistat · Drug: Matching Placebo

Interventions

  • TAK-831 Tablets.

    Also known as: TAK-831, NBI-1065844

  • DrugMatching Placebo

    Matching Placebo Tablets.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8

    EBC is a method used to investigate cerebellar-dependent learning. In EBC, a conditioned stimulus, a tone precedes but co-terminates with an unconditioned stimulus, an airpuff to the eyelid. Learning is demonstrated when an eyeblink (the conditioned response) occurs prior to the onset of the unconditioned stimulus. The percentage can range from 0% (no conditioned learning has occurred) to 100% (all responses are conditioned). Results are reported as least squares (LS) means at Day 8, determined using an analysis of variance (ANOVA).

    Time frame: Baseline, Day 8 of each treatment period

Secondary outcomes

  1. Change From Baseline in the Mean Mismatch Negativity (MMN) at Day 8

    MMN is an event related potential (ERP) evoked in response to unattended changes in background stimulation. MMN reflects an automatic process of detecting a mismatch between a deviant stimulus and a sensory-memory trace. Smaller amplitudes of MMN have been consistently identified in schizophrenia participants. MMN amplitude was measured at midline frontal electrode (Fz) of electroencephalogram (EEG). Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.

    Time frame: Baseline, Day 8 of each treatment period

  2. Change From Baseline in the Mean P300 Amplitude at Day 8

    The P300 wave is an ERP component that is elicited by the presentation of a novel, behaviorally relevant target stimulus embedded among irrelevant stimuli in a manner similar to MMN but requiring active listening and responding from participants. Auditory stimuli are presented in an oddball paradigm consisting of 1 standard tone and 1 target tone. Participants are instructed to push a button as quickly as possible when they hear the target tone but not when they hear the standard tone. P300 reflects allocation of attention and activation of immediate memory. P300 amplitude was measured at midline parietal electrode (Pz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.

    Time frame: Baseline, Day 8 of each treatment period

  3. Change From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 8

    ASSRs are evoked oscillatory responses that are entrained to the frequency and phase of temporally modulated stimuli. Individuals with schizophrenia experience subjective sensory anomalies and objective deficits on assessment of sensory function. These deficits can be produced by abnormal signaling in the sensory pathways and sensory cortex or by later-stage disturbances in the cognitive processing of such inputs. ASSR can be used to assess the integrity of sensory pathways including cortical processing. The ASSR applied a frequency stimulus of 40 hertz (Hz) and was measured at midline central electrode (Cz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.

    Time frame: Baseline, Day 8 of each treatment period

  4. Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 7

    BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating z-scores whereby the mean of the test session of a healthy person is set to 0 and the standard deviation set to 1. A Z-score of 0 represents the population mean. A composite score was calculated by averaging the 4 measures from the BACS used in the study and then calculating a z-score of the composite. The composite z-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower z-scores are indicative of lower cognitive performance. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 7, determined using an ANOVA.

    Time frame: Baseline, Day 7 of each treatment period

  5. Change From Baseline in the Mean Plasma Concentrations of D-serine and L-serine at Day 8

    Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and L-serine were measured. Results are reported as LS mean change from baseline at Day 8, determined using a mixed model for repeated measures (MMRM).

    Time frame: Day 1 and at multiple time points (up to 6 hours) to Day 8 pre-dose

  6. Change From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 8

    Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and total serine were measured. Plasma D-serine to total serine ratios were then calculated. Results are reported as LS mean change from baseline at Day 8, determined using a MMRM.

    Time frame: Baseline and Day 8 of each treatment period

  7. Mean Plasma Concentration of Luvadaxistat

    Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured.

    Time frame: Day 1 0.25 to 2 hours and 3 to 6 hours post-dose, Day 7 pre-dose, 0.25 to 2 hours and 3 to 6 hours post-dose, and Day 8 pre-dose

07

Results

Posted Feb 28, 2024

Participant flow

Participants took part in the study at 1 investigative site in the United States from 10 January 2018 to 21 December 2020.

Participant flow — Overall Study
MilestoneLuvadaxistat 500 mg, Then PlaceboPlacebo, Then Luvadaxistat 500 mgLuvadaxistat 50 mg, Then PlaceboPlacebo, Then Luvadaxistat 50 mg
Started8977
Completed6657
Not completed2320
Withdrew: Protocol violation0100
Withdrew: Early study termination due to study pause0020
Withdrew: Withdrawal by subject2200

Outcome measures

PrimaryChange From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8

EBC is a method used to investigate cerebellar-dependent learning. In EBC, a conditioned stimulus, a tone precedes but co-terminates with an unconditioned stimulus, an airpuff to the eyelid. Learning is demonstrated when an eyeblink (the conditioned response) occurs prior to the onset of the unconditioned stimulus. The percentage can range from 0% (no conditioned learning has occurred) to 100% (all responses are conditioned). Results are reported as least squares (LS) means at Day 8, determined using an analysis of variance (ANOVA).

Time frame:
Baseline, Day 8 of each treatment period
Reported as:
Least squares mean · Percent of Conditioned Responses
Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8
Percent of Conditioned ResponsesLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 80.597 ± 0.4590.319 ± 0.4320.578 ± 0.4441.344 ± 0.428
Statistical analysis
  • Luvadaxistat 50 mg vs Placebo (Reference for Luvadaxistat 50 mg) · ANOVA · p = 0.2401 · Ls mean difference: 0.278
  • Luvadaxistat 500 mg vs Placebo (Reference for Luvadaxistat 500 mg) · ANOVA · p = 0.9053 · Ls mean difference: -0.766
SecondaryChange From Baseline in the Mean Mismatch Negativity (MMN) at Day 8

MMN is an event related potential (ERP) evoked in response to unattended changes in background stimulation. MMN reflects an automatic process of detecting a mismatch between a deviant stimulus and a sensory-memory trace. Smaller amplitudes of MMN have been consistently identified in schizophrenia participants. MMN amplitude was measured at midline frontal electrode (Fz) of electroencephalogram (EEG). Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.

Time frame:
Baseline, Day 8 of each treatment period
Reported as:
Least squares mean · microvolts
Change From Baseline in the Mean Mismatch Negativity (MMN) at Day 8
microvoltsLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
Change From Baseline in the Mean Mismatch Negativity (MMN) at Day 8-0.239 ± 0.3630.669 ± 0.3820.594 ± 0.492-0.154 ± 0.501
SecondaryChange From Baseline in the Mean P300 Amplitude at Day 8

The P300 wave is an ERP component that is elicited by the presentation of a novel, behaviorally relevant target stimulus embedded among irrelevant stimuli in a manner similar to MMN but requiring active listening and responding from participants. Auditory stimuli are presented in an oddball paradigm consisting of 1 standard tone and 1 target tone. Participants are instructed to push a button as quickly as possible when they hear the target tone but not when they hear the standard tone. P300 reflects allocation of attention and activation of immediate memory. P300 amplitude was measured at midline parietal electrode (Pz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.

Time frame:
Baseline, Day 8 of each treatment period
Reported as:
Least squares mean · microvolts
Change From Baseline in the Mean P300 Amplitude at Day 8
microvoltsLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
Change From Baseline in the Mean P300 Amplitude at Day 8-2.019 ± 1.680.608 ± 1.681.102 ± 1.772.595 ± 1.86
SecondaryChange From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 8

ASSRs are evoked oscillatory responses that are entrained to the frequency and phase of temporally modulated stimuli. Individuals with schizophrenia experience subjective sensory anomalies and objective deficits on assessment of sensory function. These deficits can be produced by abnormal signaling in the sensory pathways and sensory cortex or by later-stage disturbances in the cognitive processing of such inputs. ASSR can be used to assess the integrity of sensory pathways including cortical processing. The ASSR applied a frequency stimulus of 40 hertz (Hz) and was measured at midline central electrode (Cz) of EEG. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 8, determined using an ANOVA.

Time frame:
Baseline, Day 8 of each treatment period
Reported as:
Least squares mean · microvolts-squared
Change From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 8
microvolts-squaredLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
Change From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 82.135 ± 8.83-16.282 ± 9.319.411 ± 20.49.203 ± 20.9
SecondaryChange From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 7

BACS is a cognition assessment battery and includes brief assessments of reasoning and problem solving, verbal fluency, attention, verbal memory, working memory and motor speed. The primary measure from each test is standardized by creating z-scores whereby the mean of the test session of a healthy person is set to 0 and the standard deviation set to 1. A Z-score of 0 represents the population mean. A composite score was calculated by averaging the 4 measures from the BACS used in the study and then calculating a z-score of the composite. The composite z-score indicates how much higher or lower the participants cognition is compared to a healthy person. Lower z-scores are indicative of lower cognitive performance. Baseline was defined as the last observation prior to the dose of study treatment in the corresponding period. Results are reported as LS mean change from baseline at Day 7, determined using an ANOVA.

Time frame:
Baseline, Day 7 of each treatment period
Reported as:
Least squares mean · z-score
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 7
z-scoreLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 72.574 ± 2.515.070 ± 2.555.696 ± 1.41-0.075 ± 1.43
SecondaryChange From Baseline in the Mean Plasma Concentrations of D-serine and L-serine at Day 8

Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and L-serine were measured. Results are reported as LS mean change from baseline at Day 8, determined using a mixed model for repeated measures (MMRM).

Time frame:
Day 1 and at multiple time points (up to 6 hours) to Day 8 pre-dose
Reported as:
Least squares mean · mg / liter
Change From Baseline in the Mean Plasma Concentrations of D-serine and L-serine at Day 8
mg / literLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
D-serine0.0402 ± 0.00632-0.000892 ± 0.006370.0398 ± 0.007100.00212 ± 0.00712
L-serine0.669 ± 0.479-0.543 ± 0.483-1.09 ± 0.514-0.304 ± 0.516
SecondaryChange From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 8

Blood samples were collected at pre-specified timepoints and plasma concentrations of D-serine and total serine were measured. Plasma D-serine to total serine ratios were then calculated. Results are reported as LS mean change from baseline at Day 8, determined using a MMRM.

Time frame:
Baseline and Day 8 of each treatment period
Reported as:
Least squares mean · ratio
Change From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 8
ratioLuvadaxistat 50 mgPlacebo (Reference for Luvadaxistat 50 mg)Luvadaxistat 500 mgPlacebo (Reference for Luvadaxistat 500 mg)
Change From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 80.00293 ± 0.0008550.000590 ± 0.0008630.00561 ± 0.0009940.000620 ± 0.000997
SecondaryMean Plasma Concentration of Luvadaxistat

Blood samples were collected at pre-specified timepoints and plasma concentrations of luvadaxistat were measured.

Time frame:
Day 1 0.25 to 2 hours and 3 to 6 hours post-dose, Day 7 pre-dose, 0.25 to 2 hours and 3 to 6 hours post-dose, and Day 8 pre-dose
Reported as:
Mean · nanograms / milliliter
Mean Plasma Concentration of Luvadaxistat
nanograms / milliliterLuvadaxistat 50 mgLuvadaxistat 500 mg
Day 1 - Post-dose (0.25 to 2 hours)253.4 ± 199.3700.4 ± 783.0
Day 1 - Post-dose (3 to 6 hours)47.66 ± 35.64671.1 ± 473.1
Day 7 - Pre-dose8.749 ± 19.21278.92 ± 229.90
Day 7 - Post-dose (0.25 to 2 hours)203.5 ± 199.61184 ± 482
Day 7 - Post-dose (3 to 6 hours)38.94 ± 26.23301.5 ± 177.2
Day 8 - Pre-dose3.366 ± 2.72621.61 ± 14.65

Adverse events

Collected over 8-day treatment period for each of treatment periods 1 and 2 (separated by washout of up to 21 days) and up to 30 days follow-up after last dose of study treatment. Up to a maximum of 67 days for overall timeframe.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/29 (0%)0/29 (0%)0/29 (0%)
Luvadaxistat 500 mg0/15 (0%)0/15 (0%)0/15 (0%)
Luvadaxistat 50 mg0/14 (0%)0/14 (0%)1/14 (7.1%)
Most frequent other events
Most frequent other events
EventPlaceboLuvadaxistat 500 mgLuvadaxistat 50 mg
DyspepsiaGastrointestinal disorders0/290/151/14

Baseline characteristics

The safety analysis set included all participants who were randomized and received at least 1 dose of double-blind study drug.

Age, Categorical
Age, Categorical(Participants)Luvadaxistat 500 mg, Then PlaceboPlacebo, Then Luvadaxistat 500 mgLuvadaxistat 50 mg, Then PlaceboPlacebo, Then Luvadaxistat 50 mgTotal
<=18 years00000
Between 18 and 65 years897731
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Luvadaxistat 500 mg, Then PlaceboPlacebo, Then Luvadaxistat 500 mgLuvadaxistat 50 mg, Then PlaceboPlacebo, Then Luvadaxistat 50 mgTotal
Female02125
Male876526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Luvadaxistat 500 mg, Then PlaceboPlacebo, Then Luvadaxistat 500 mgLuvadaxistat 50 mg, Then PlaceboPlacebo, Then Luvadaxistat 50 mgTotal
Hispanic or Latino00101
Not Hispanic or Latino896730
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Luvadaxistat 500 mg, Then PlaceboPlacebo, Then Luvadaxistat 500 mgLuvadaxistat 50 mg, Then PlaceboPlacebo, Then Luvadaxistat 50 mgTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American886426
White01023
More than one race00000
Unknown or Not Reported00101
08

Study locations

1 site
  • CBH Health, LLC
    Gaithersburg, Maryland 20877, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2020, 35 months.

Results were first posted in Feb 2024, 3 years 2 months after primary completion. A results delay was requested in Dec 2021.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 35 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 2, 2017
StartActual
Jan 10, 2018
Primary completionActual
Dec 21, 2020
CompletionActual
Dec 21, 2020
Results delay requested
Dec 7, 2021
Results first posted
Feb 28, 2024
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03359785
Collaborators
Takeda
Responsible party
Sponsor
First posted
Dec 2, 2017
Start date
Jan 10, 2018
Primary completion
Dec 21, 2020
Completion
Dec 21, 2020
Results posted
Feb 28, 2024
Last update
Feb 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvadaxistat

Start the discussion